Name: Plus Therapeutics, Inc. (PSTV) Financial Statements
Creator: FinSpry

Plus Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Plus Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	5.82	4.91	0.22	0.00	0.30
Cost of Revenue	10.58	9.69	9.70	5.32	2.70
Gross Profit	-4.76	-4.78	-9.47	-5.32	-2.40
Operating Expenses
Research & Development	10.58	9.69	9.70	5.57	0.00
Selling, General & Administrative	9.94	8.54	10.24	6.85	6.41
Operating Expenses	9.94	13.32	19.71	12.43	6.41
Operating Income	-14.70	-13.32	-19.71	-12.43	-8.80
Other Income/Expense
Interest Income	0.27	0.40	0.15	0.02	0.05
Interest Expense	-0.18	0.40	0.71	0.93	-1.11
Other Income/Expense	1.62	0.00	0.00	-0.06	2.40
Income
Income Before Tax	-12.98	-13.32	-20.28	-13.40	-8.24
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-12.98	-13.32	-20.28	-13.40	-8.24
Net Income - Continuous Operations	-12.98	-13.32	-20.28	-13.40	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-13.97	-12.29	-18.95	-12.07	-8.44
EBIT	-14.70	-12.92	-19.56	-12.47	-8.80
Depreciation & Amortization	0.72	0.63	0.62	0.40	0.37
Earnings Per Share
Basic EPS	-2.00	-4.00	-12.00	-17.00	-28.00
Diluted EPS	-2.00	-4.00	-12.00	-17.00	-28.00
Basic Shares Outstanding	6.64	3.14	1.75	0.81	0.30
Diluted Shares Outstanding	7.70	3.14	1.75	0.81	0.30